For example, It has been established that in a mouse model of mucopolysaccharidosis type I (MPS I) (α-L-iduronidase (IDUA) deficiency, IDUA−/− line), gene therapy normalizes levels of heparan and dermatan sulfates in tissues and urine, and reduces the HCII–thrombin complex, a biomarker of disease severity [46,47]. Here, SERPIND1 is linked to Scheie syndrome.